Search results

1755 results

Sorted by Relevance . Sort by Date

  1. Acute coronary syndromes

    In development [GID-NG10085] Expected publication date: 18 November 2020

  2. Shared decision making

    In development [GID-NG10120] Expected publication date: 17 June 2021

  3. Caesarean section (update)

    In development [GID-NG10081] Expected publication date: 31 March 2021

  4. Inducing labour (update)

    In development [GID-NG10082] Expected publication date: 14 October 2021

  5. Mental wellbeing at work

    In development [GID-NG10140] Expected publication date: 15 December 2021

  6. Postnatal care

    In development [GID-NG10070] Expected publication date: 07 April 2021

  7. Lenalidomide with rituximab for previously treated follicular lymphoma (TA627)

    Evidence-based recommendations on lenalidomide (Revlimid) with rituximab for previously treated follicular lymphoma (grade 1 to 3A) in adults

  8. Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears (TA369)

    Evidence-based recommendations on ciclosporin (Ikervis) for treating dry eye disease that has not improved despite treatment with artificial tears

  9. Bortezomib for previously untreated mantle cell lymphoma (TA370)

    Evidence-based recommendations on bortezomib (Velcade) for treating previously untreated mantle cell lymphoma in adults

  10. Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)

    Evidence-based recommendations on abatacept, adalimumab, etanercept and tocilizumab for treating polyarticular juvenile idiopathic arthritis (JIA)

  11. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab…

  12. Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378)

    Evidence-based recommendations on ramucirumab (Cyramza)